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OBJECTIVE
Recent large trials yield conflicting results on the association between incretin-
based therapies (IBTs) and diabetic retinopathy (DR). We examined whether IBTs
increase DR risk compared with other antihyperglycemics.
RESEARCH DESIGN AND METHODS
We implemented an active comparator, new-user cohort design using a nationwide
20% random sample of fee-for-service U.S. Medicare beneficiaries aged 65 years or
older with Parts A, B, and D coverage between 2007 and 2015. We identified the
following cohorts without prior treatment for retinopathy: dipeptidyl peptidase
4 inhibitors (DPP4i) versus sulfonylureas (SU), DPP4i versus thiazolidinediones
(TZD), glucagon-likepeptide-1 receptor agonists (GLP1RA) versus long-acting insulin
(LAI), andGLP1RA versus TZD. Primary outcomewas advanced diabetic retinopathy
requiring treatment (ADRRT), defined as a procedure code for retinopathy treatment.
Incident diabetic retinopathy (IDR), identified by a diagnosis code, was a secondary
outcome. We estimated propensity scores to balance confounders and adjusted
hazard ratios (95% CI) using weighted Cox proportional hazards models.
RESULTS
We identified 213,652 eligible patients. During a median duration of 0.58 to 0.87
years across comparisons, with a rate from 6.0 to 12.8 per 1,000 person-years, IBTs
were not associated with increased ADRRT or IDR risk. The adjusted hazard ratios
(95% CI) for ADRRTwere 0.91 (0.79–1.04) by comparing DPP4i to SU (n = 39,292 and
87,073); 0.91 (0.75–1.11), DPP4i to TZD (n = 51,410 and 22,231); 0.50 (0.39–0.65),
GLP1RA to LAI (n = 9,561 and 82,849); and 0.75 (0.53–1.06), GLP1RA to TZD (n =
10,355 and 27,345).
CONCLUSIONS
Our population-based cohort study of older U.S. adults with diabetes suggests that
IBTs used for approximately 1 year do not increase the DR risk.
Incretin-based therapies (IBTs), including glucagon-like peptide-1 receptor agonists
(GLP1RA) and dipeptidyl peptidase 4 inhibitors (DPP4i), control blood glucose by
potentiation of incretin receptor signaling (1). Safety concerns regarding IBTs have
focused on pancreatitis (2), pancreatic cancer (3), medullary thyroid cancer (1), and
heart failure (4,5). Recent cardiovascular trials have led to concerns that IBTs may
increase the risk of diabetic retinopathy (DR) compared with placebo. The Trial to
Evaluate Cardiovascular andOther Long-termOutcomeswith Semaglutide in Subjects
with Type 2 Diabetes (SUSTAIN-6) reported a significantly higher rate of retinopathy
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complicationswith the GLP1RA semaglu-
tide (14.9 vs. 8.6 events/1,000 person-
years over 2.1 years of treatment; hazard
ratio [HR] 1.76 [95% CI 1.11–2.78]) (6).
The Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial showed
a statistically nonsignificant higher in-
cidence of retinopathy complications
with another GLP1RA, liraglutide (6 vs. 5
events/1,000 person-years over a me-
dian 3.8 years of treatment; HR 1.15
[0.87–1.52]) (7). The Trial Evaluating Car-
diovascular Outcomes With Sitagliptin
(TECOS) study showed patients on DPP4i
sitagliptin had a higher retinopathy
frequency (2.8% vs. 2.2%, median follow-
up of 3.0 years) (8), whereas the Ex-
enatide Study of Cardiovascular Event
Lowering (EXSCEL) trial showed no in-
creased retinopathy frequency in patients
on GLP1RA exenatide (2.9% vs. 3.2%, me-
dian follow-up of 3.2 years) (9). The low
retinopathy frequency in TECOS and EX-
SCEL trials could be explained by the ab-
sence of systematic examinations; none of
the published trials systematically assessed
retinopathy complications. Therefore, we
conducted this large active comparator,
new-user (ACNU) cohort study to exam-
ine whether the use of IBTs, as compared
with therapeutic alternatives, is associ-
ated with an increased risk of DR.
RESEARCH DESIGN AND METHODS
Data Source
Medicare provides medical coverage for
the U.S. population aged 65 years and
older. The University of North Carolina
(UNC) has access to longitudinal claims
data for a 20% random sample of all fee-
for-service Medicare beneficiaries with
Parts A (inpatient), B (outpatient physi-
cian services), and D (dispensed prescrip-
tion drugs) coverage for at least 1 month
from January 2007 to September 2015.
The study protocol was registered in
the European Network of Centres for
Pharmacoepidemiology and Pharma-
covigilance (ENCePP) electronic regis-
ter of studies (www.encepp.eu/encepp/
viewResource.htm?id=17777) and ap-
proved by the UNC institutional review
board.
Study Population
The eligible population consisted of
Medicare enrollees aged 65 years or older
with at least 12 months of continuous
enrollment in Medicare Parts A, B and D
and without Health Maintenance Orga-
nization coverage before initiation and
during follow-up. We identified all new
users of a therapy of interest based on
the first dispensing of a prescription
in a given drug class after a 12-month
washout for that drug class. Patients
entered the cohort on the date of dis-
pensing of the first prescription. As we
obtained prescription data (Part D) start-
ing from 1 January 2007, thus the earliest
index date was 1 January 2008. As IBTs
are typically second-line therapies (10)
and the DR risk increases with increased
diabetes duration (11), it is necessary to
compare IBTs with drugs used at a similar
stage of diabetes (12). Using an active
comparator study design helps to miti-
gate bias by only selecting individuals
with an indication for initiating a second-
line antidiabetes treatment, identify-
ing individuals at a similar point in their
disease management and ensuring only
adverse events after drug initiation are
evaluated (12). We identified new users of
the following comparisons, DPP4i versus
sulfonylureas (SU), DPP4i versus thia-
zolidinediones (TZD), GLP1RA versus long-
acting insulin (LAI), and GLP1RA versus
TZD, and we excluded new users who took
the other drug in the 12 months prior to
initiation. Thus, the number of partici-
pants and events for a specific drug class
varied across comparisons. Given these
antihyperglycemia agents are primarily
indicated for diabetes treatment (10),
we did not restrict cohorts to those
with a diagnosis code for diabetes. As
early detection can reduce DR progression
and prevent vision loss, patients with
diabetes in the U.S. are recommended
to have an eye exam at least every 2 years
(10,11). As only patients with diabetes
who had an eye exam could receive eye
disease diagnoses or codes for specific
treatments, we required cohort partici-
pants to have at least one eye examina-
tion in the 12 months prior to the index
date. We identified eye examinations us-
ing Current Procedural Terminology (CPT)
codes (Supplementary Table 1) and ex-
cluded patients with blindness and low
vision (ICD-9-CM 369.XX), retinopathy
treatment (described below), or vitrec-
tomy before the index date. As current
guidelines recommend treatment only
for severe DR (12), we did not exclude
patients with a DR diagnosis (ICD-9-CM
362.0X) without treatment. Last, as
patients with congestive heart failure
are less likely to initiate TZD (4), we ex-
cluded patients with a diagnosis of con-
gestive heart failure in the 12 months
prior to the first prescription when com-
paring IBTs to TZD.
DR Outcome
Our primary outcome was advanced di-
abetic retinopathy requiring treatment
(ADRRT) as a proxy for incident retinop-
athy severe enough to require treatment
(in patients without retinopathy at co-
hort entry) and worsening of preexisting
retinopathy requiring incident treatment
(in patients with DR but no retinopathy
treatment at cohort entry). We used
CPT and Healthcare Common Procedure
Coding System (HCPCS) code to identify
these treatments (Supplementary Table
1) (11). The primary definition was based
on receipt of one of the following pro-
cedures with a DR or diabetes diagnosis
code on the same claim: 1) photocoag-
ulation (CPT 67228, 67210), 2) vitrectomy
(CPT 67036, 67038–67042), and 3) in-
travitreal injection (CPT 67028) of anti–
vascular endothelial growth factor agents
(ranibizumab, aflibercept, orbevacizumab)
or corticosteroid (triamcinolone, dexa-
methasone, or fluocinolone). Because
medication-specific codes were not
available immediately after U.S. Food
and Drug Administration approval and
bevacizumab lacks a code specific to oc-
ular use (13), we also included claims
for intravitreal injection of unclassified/
miscellaneous drug codes. To minimize
miscoding or misclassification bias, we
required all HCPCS drug codes to be
jointly used with an intravitreal injection
CPT code. As some of these therapies are
approved to treat age-related macular
degeneration (AMD) (13), we excluded
treatments with the following AMD
diagnosis codes, ICD-9-CM 362.50,
362.52, 362.42, or 362.43. To capture
untreated retinopathy (11), we defined
our secondary outcome as incident di-
abetic retinopathy (IDR), identified by
diagnosis ICD-9-CM362.0X.When assess-
ing IDR, patients with DR at baseline were
excluded.
Follow-up
Follow-up started at the first prescription
and ended with the earliest of the fol-
lowing events: 1) 30 days after treat-
ment discontinuation (the date of last
prescription plus a 90-day grace pe-
riod), 30 days after switching to or adding
the comparator drug class, or 30 days
after the end of Medicare Part D enroll-
ment, whichever came first; 2) end of
enrollment for Medicare Parts A or B; 3)
death; 4) end of study (30 September
2015); or 5) a claim for retinopathy treat-
ment (for secondary outcomes analyses,
a claim with a retinopathy diagnosis). We
used the first DR treatment date to de-
fine the outcome date (first DR diagno-
sis for secondary outcome). Our primary
analysis was as treated (Supplementary
Fig. 1), using follow-up based on actual
exposure to the initial antihyperglyce-
mia treatment. Patients were defined
as exposed to the initial treatment un-
til treatment changed, including index
drug class discontinuation or switching
to or addition of a drug from the alter-
native class in the comparison. Treat-
ment discontinuation was defined as no
refills within a period equal to the pre-
scribed duration of the last filled pre-
scription plus a 90-day grace period (14).
In the SUSTAIN-6 trial, increased reti-
nopathy events with semaglutide oc-
curred within the first 2 months (7).
The mechanisms for incretin-associated
DR complications are not clear, but one
theory is that it results from a rapid
glycemic control (15). Thus,we assumed
treatment-related retinopathy would oc-
cur soon after treatment initiation. To
account for the time required between
noticing ocular disturbances and receiv-
ing an eye exam (the “latency” period),
we considered retinopathy events within
30 days after treatment changes to be
related to the initial treatment.
Statistical Analyses
We examined a variety of baseline char-
acteristics for each cohort, defined based
on claims during the 12 months prior to
the index prescription (Table 1). These
covariates included demographics, di-
abetes severity, comorbidities, come-
dications, health care utilization, and
socioeconomic status (16). To control
for factors that may influence the deci-
sion to prescribe a given treatment, we
estimated propensity scores (PS) for
each patient in each comparison using
these variables. We did not use PS for
the comparison on three groups simul-
taneously (DPP4i, SU, and TZD group
and GLP1RA, TZD, and LAI group), as
IBT initiators in each comparison are
not the same population. To directly
compare the estimates across two
comparator groups for each of the IBTs,
we standardized the covariate distri-
bution of comparator initiators to the
covariate distribution of IBT initiators
using standardized mortality/morbidity
ratio (SMR) weights [PS/(1 2 PS)] (17).
SMR weighting creates comparator
cohorts with the same covariate distri-
bution as in the IBT cohorts, as evinced
by standardized differences of covariates
close to zero after weighting.
We calculated crude incidence by di-
viding the number of patients with the
outcome by the total amount of obser-
vation time for each exposure group,
with CIs based on the Poisson distri-
bution. We constructed SMR-weighted
(adjusted) Kaplan-Meier curves to com-
pare the cumulative incidence of ADRRT
(18). We fit Cox proportional hazards
models in the PS-weighted populations
to estimate HRs and 95% CIs for DR
associated with the use of IBTs versus
comparators.
Secondary Analyses
Approximately 10% of fee-for-service
Medicare beneficiaries initiating the
drugs of interest had CPT II codes for
HbA1c, blood pressure, and cholesterol
categories (Table 1). These patients
were likely seen by providers who par-
ticipated in programs such as Healthcare
Effectiveness Data and Information Set
performance measurement in the account-
able care organizations or the Physician
Quality Reporting System, which require
physicians to regularly report these clini-
cal measures to Centers for Medicare &
Medicaid Services (19,20). We performed
20 multiple imputations for these clinical
measures to control for confounding us-
ing fully conditional specification with
logistic regression (21,22), then esti-
mated adjusted HRs balancing mea-
sured and imputed covariates in each
of the 20 imputed data sets using PS
weighting, and then pooled the results
across the imputations. We then stratified
by HbA1c tertiles (,7% [53 mmol/mol],
7–9% [53–75 mmol/mol], and .9%
[75 mmol/mol]). To assess whether
the risk varied with duration of use,
we estimated separate HRs for the
first 6 months, 6–12 months, and after
12months. Additionally, we evaluated
whether the risk varied across patients
with and without preexisting untreated
DR, hypertension, and use of ACE inhib-
itors or angiotensin receptor blockers
(ARBs) at cohort entry and the risk for
each individual IBT.
Sensitivity Analyses
To assess the robustness of estimated
DR risk, we performed several sensitivity
analyses. First, we changed the latency
period from 30 days to 0, 60, 90, and
180 days. Second, we performed an
analysis based on initial treatment
(Supplementary Fig. 2), ignoring treat-
ment changes during follow-up. This
approach mimics the intention-to-treat
analysis in a randomized trial. The follow-
up ends with the earliest of the fol-
lowing events: 3 years after initiation,
death, end of enrollment for Medicare
Parts A or B, end of study (30 September
2015), or a retinopathy treatment claim.
Third, we modified our primary outcome
to require a DR diagnosis in the primary,
secondary, or tertiary position within the
procedure claim. Fourth, as somepatients
with diabetes undergo eye exams less
frequently than recommended (22) and
only patients who had an eye exam could
receive treatment for retinopathy, we
excluded patients without an eye exam
after cohort entry, recognizing this intro-
duces selection bias. Fifth, as intensive
use of insulin has an “early worsening”
effect on retinopathy (23), we censored
patients receiving LAI during follow-up
when compared to SU or TZD. Sixth, we
censored patients when they received
medications that may induce or worsen
(24,25) or slow retinopathy progres-
sion (fenofibrate [11]) (Supplementary
Table 2). The third through sixth sensi-
tivity analyses were based on our pri-
mary analysis (as treated, 30-day latency
period). Seventh, we conducted analysis
using multivariable-adjusted Cox regres-
sion. Last, we assessed our secondary
outcome, IDR, using as-treated analysis
with different latency periods (0, 30, 60,
90, and 180 days).
RESULTS
Study Population
We identified 213,652 eligible patients
from 487,057 initiators of at least one
drug of interest, including 126,365 ini-
tiators for the DPP4i versus SU com-
parison, 73,641 initiators for DPP4i
versus TZD comparison, 92,410 initiators
for GLP1RA versus LAI comparison, and
37,700 initiators for GLP1RA versus
TZD comparison (Supplementary Fig.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exam to index date was about 120 days
with interquartile range from 50 to 221
days: DPP4i vs. SU 117 (49–214) vs.
122 (51–221), DPP4i vs. TZD 119 (50–
217) vs. 116 (48–218), GLP1RA vs. LAI
120 (50–220) vs. 122 (51–221), and
GLP1RA vs. TZD 118 (49–216) vs.
116 (49–216). We present the crude
and weighted baseline covariate dis-
tributions in Table 1. The mean age
ranged between 72.5 and 76.9 years,
38.8% to 42.3% were men, and the
frequency of preexisting retinopathy
ranged from 10.7% (GLP1RA initiators)
to 14.2% (LAI initiators). Overall, the
prevalence of comorbidities was sim-
ilar in the comparison cohorts except
LAI initiator cohort, who was more
likely to have diabetes complications,
cardiovascular diseases, chronic obstruc-
tive pulmonary disease, and chronic
kidney disease compared with the
GLP1RA cohort. In the third column of
each comparison in Table 1, we present
PS-weighted covariate distributions for
the comparator drug initiators. The vir-
tually identical distribution of the covar-
iates in IBT initiators and the PS-weighted
comparator initiators shows that we were
able to balance all measured covariates
and, thus, remove confounding by these
covariates. The standardized differences
before and after weighting are presented
in Supplementary Tables 3 and 4. In the
small subset of patients with information
on categories of HbA1c, blood pressure,
and LDL cholesterol, the distribution
of these clinical measures was similar
between IBTs and comparators, except
that the LAI initiator cohort was more
likely to have a higher HbA1c level
(.9% [75 mmol/mol]) compared with
the GLP1RA initiator cohort. The distri-
bution of clinical covariates was well
balanced by PS weighting after multiple
imputation.
IBTs and ADRRT
In Table 2, we present results of the
primary as-treated analysis for ADRRT
risk. Among the eight cohorts, the me-
dian treatment duration ranged from
0.58 to 0.87 years, the crude incidence
of ADRRT ranged from 6.0 to 12.8 events
per 1,000 person-years, and the average
incidence was 8.7 per 1,000 person-
years. After adjusting for confounding,
DPP4i was not associated with a risk of
ADRRT when compared to SU (HR 0.91
[95% CI 0.79–1.04]) or TZD (0.91 [0.75–
1.11]), and GLP1RA was not associated
with increased risk when compared to
TZD (0.75 [0.53–1.06]) but showed a
decreased risk compared to LAI (0.50
[0.39–0.65]). We present weighted
Kaplan-Meier curves for IBTs and com-
parators in Fig. 1. The curves are similar
except for the GLP1RA versus LAI com-
parisons, in which LAI was associated
with a higher risk of ADRRT.
The results for analysis based on mul-
tiple imputation for missing clinical
measures (Supplementary Table 5) and
subsequent analysis (Supplementary Ta-
ble 6) stratified by HbA1c are consistent
with primary results. When stratified by
duration and preexisting retinopathy
(Table 3) and baseline hypertension and
ACE inhibitor/ARB treatment (Supple-
mentary Table 7), the HRs of ADRRT did
not differ meaningfully and the CIs widely
overlap. We, therefore, refrained from
statistical testing for interactions. When
stratified by individual IBT, both exena-
tide and liraglutide showed a lower risk
compared with LAI, and only exenatide
showed a lower risk compared with
TZD (Supplementary Table 8).
Sensitivity Analyses
Overall, results of sensitivity analyses for
ADRRT were consistent with our primary
analysis (Supplementary Tables 9–15).
However, we observed a decreased risk
in the GLP1RA versus TZD comparison
using a 180-day latency period (HR 0.68
[95% CI 0.50–0.93]) (Supplementary
Table 9) or initial treatment analysis
(0.75 [0.58–0.98]) (Supplementary Table
10). Our analyses for secondary outcome,
IDR, also suggested similar results, ex-
cept for a slightly lower risk for GLP1RA
compared with TZD (e.g., HR 0.85 [0.75–
0.97] using a 30-day latency period)
(Supplementary Table 16).
CONCLUSIONS
Our study is the first large, population-
based study to examine the effect of IBTs
on the risk of DR among older adults with
type 2 diabetes. Our results suggested
that, compared with therapeutic alter-
natives, initiating IBTs is not associated
with an increased risk of DR. Similar
results were observed for DPP4i and
GLP1RA, and, overall, the results were
consistent across secondary and sensi-
tivity analyses.
Unmeasured Confounding
Because some risk factors for DR may
not be well captured in claims data (26),
wemainly rely on the ACNU study design
to reduce the potential for unmeasured
confounding by indication. This study
approach is a proven, effective method
for minimizing the risk of confounding by
indication. For example, in our previous
study on cancer incidence among pa-
tients initiating insulin with glargine
versus human NPH insulin (27), the
strongest predictor of the need for in-
sulin in patients with type 2 diabetes,
Table 2—Crude and adjusted HRs for ADRRT associated with use of IBTs compared with therapeutic alternatives*













DPP4i vs. SU DPP4i 39,292 0.75 (0.41–1.67) 50,222 349 6.9 (6.3–7.7) 1.10 (0.97–1.25) 0.91 (0.79–1.04)
SU 87,073 0.87 (0.42–2.01) 129,099 772 6.0 (5.6–6.4) 1.00 (reference) 1.00 (reference)
DPP4i vs. TZD DPP4i 51,410 0.80 (0.41–1.70) 67,327 520 7.7 (7.1–8.4) 0.85 (0.73–0.98) 0.91 (0.75–1.11)
TZD 22,231 0.74 (0.41–1.52) 26,984 253 9.4 (8.3–10.6) 1.00 (reference) 1.00 (reference)
GLP1RA vs. LAI GLP1RA 9,561 0.59 (0.41–1.21) 9,462 66 7.0 (5.5–8.9) 0.49 (0.39–0.63) 0.50 (0.39–0.65)
LAI 82,849 0.67 (0.41–1.66) 106,699 1,368 12.8 (12.2–13.5) 1.00 (reference) 1.00 (reference)
GLP1RA vs. TZD GLP1RA 10,355 0.58 (0.41–1.17) 9,895 122 12.3 (10.3–14.7) 1.16 (0.94–1.42) 0.75 (0.53–1.06)
TZD 27,345 0.78 (0.42–1.57) 34,232 334 9.8 (8.8–10.9) 1.00 (reference) 1.00 (reference)
IQR, interquartile range. *Analysis based on as-treated exposure definition, latency period is 30 days. †PS-weighted HRs were standardized to the
distribution of baseline covariates in IBT initiators.
BMI, had no influence on the choice
of insulin because both cohorts in the
ACNU design were candidates for either
drug, thereby effectively removing un-
measured confounding that could be
associated with differences in BMI be-
tween cohorts.
In this study, Table 1 presents evidence
that treatment choice between IBTs and
comparator was not meaningfully af-
fected by measured markers of diabetes
severity, including codes for neuropathy
and nephropathy and broad categories
of HbA1c levels, except for the GLP1RA
versus LAI comparison. This finding is
further evidence that if none of the mea-
sured risk factors for DR affect the choice
between initiating these drug classes, it
is unlikely that other unmeasured risk
factors that would impact our study out-
comes also influence treatment choice.
Additionally, we performed multiple
imputation of key diabetes measures
to further control for unmeasured con-
founding. Using this approach is sta-
tistically valid even though we have
approximately 90% of missing data for
the categories of HbA1c, blood pressure,
and LDL cholesterol because the pro-
portion of variables with missing data
are small (4 out of 50 variables) and the
size of the validation study (i.e., those
with HbA1c, blood pressure, and LDL
cholesterol values) is large (several hun-
dred patients in each category) (28,29).
The HRs changed slightly after multiple
imputation for these clinical measures,
indicating HbA1c had little effect on
treatment choice except for GLP1RA
versus insulin (both true and imputed
clinical measures were not balanced for
this comparison). However, as we only
have broad HbA1c categories and have
no separate category for very high
HbA1c (e.g., .12% [108 mmol/mol]),
there might be residual confounding
by HbA1c, especially in our highest
category (.9% [75 mmol/mol]).
IBT and Retinopathy Risk
As both albiglutide and dulaglutide
were approved in 2014 in the U.S.
(30,31), the majority of GLP1RA co-
horts are exenatide and liraglutide
initiators. GLP1RA therapies were not
associated with an increased DR risk
compared with therapeutic alterna-
tives in our study, which is in line
with the results of the EXSCEL (9)
and LEADER trials (7). A few possible
reasons may explain the inconsis-
tency between our results and the
significant findings in the SUSTAIN-6
Figure 1—SMR-weighted Kaplan-Meier plots of ADRRT. A: DPP4i vs. SU cohort. HR 0.91 (95% CI 0.79–1.04). B: DPP4i vs. TZD cohort. HR 0.91 (95% CI
0.75–1.11). C: GLP1RA vs. LAI cohort. HR 0.50 (95% CI 0.39–0.65). D: GLP1RA vs. TZD cohort. HR 0.75 (95% CI 0.53–1.06). SMR weights create
a pseudo-population of the untreated (comparators: SU, TZD, or LAI), which has the same covariate distribution as the treated (IBT). Every patient
receiving IBT has a weight of 1, whereas every patient in the comparator group is weighted by PS/(12 PS). The risks on the y-axis were obtained by
a SMR-weighted Cox model (weighting comparator drug initiators by the PS odds [PS/(12 PS)]). HR treats comparators as reference, and adjusted






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(6) and TECOS (8) trials. First, the car-
diovascular trials either did not assess
DR (7–9) or grade DR severity (6) at
baseline. Although randomization tends
to minimize bias related to preexisting
retinopathy, due to the relatively small
numbers in these trials, it is possible
that, by chance, the degree of retinop-
athy was not matched between the two
arms (32). Second, it is possible that the
effect of semaglutide on retinopathy
truly exists, and the risk of DR differs
across the class of GLP1RA, whereas
our cohorts do not include semaglu-
tide. Third, our study was limited to the
elderly Medicare population and may
not reflect outcomes in younger pa-
tients in trials who may have a lower
risk of retinopathy. Last, the real-world
adherence and persistence to treat-
ment is typically lower (14) than trials,
and the median duration for treat-
ment in our cohorts ranged from 0.58
to 0.87 years.
GLP1RA was associated with a lower
risk for DR (both ADRRT and IDR) com-
pared with LAI and with a lower risk of IDR
compared with TZD. Although results ad-
justing for HbA1c based on multiple im-
putation and subgroup analysis did not
change much from primary analysis, re-
sidual confounding could not completely
be ruled out. However, it is also possi-
ble that GLP1RA truly reduces the reti-
nopathy risk. Topical administration of
either GLP1RA (33) or DPP4i (34) pre-
vents retinal neurodegeneration in mice.
Further, the rapid glycemic control when
initiating LAI is associated with early
worsening of DR (23,35–37), which could
contribute to this finding. TZD’s effects
on macular edema (24,38) may contrib-
ute to the observed GLP1RA’s lower risk
of IDR as well, although evidence has
been conflicting (38,39). DPP4i shows a
trend (statistically insignificant) of de-
creased risk of DR (both ADRRT and
IDR), which could be explained by the
observed preclinical beneficial effect on
the retina (34).
Strengths
Our study has several strengths. With
data that are representative of U.S. older
adults, our large observational cohort
study is the first real-world evidence
designed to assess the effect of IBTs
on degree of DR severity. Our ACNU de-
sign comparing IBT initiators with pa-
tients initiating a guideline-recommended
clinical alternative both reduces the
potential for unmeasured confounding
by indication and provides a clinically
appropriate comparison. We systemi-
cally assessed the potential for residual
confounding and used rigorous statisti-
cal adjustment to minimize remaining
imbalances between treatment cohorts
compared.
We used several methods to minimize
detection bias, recognizing that patients
who do not have eye exams cannot have
severe DR diagnosed or treatments ap-
plied. First, we required baseline eye
exams within the year before cohort
entry, and our data showed that the
duration between last eye exam and
index date was well balanced between
IBTs and comparators. Second, as other
eye conditions may evoke greater atten-
tion from eye care professionals, lead-
ing to earlier detection and treatment of
DR, we systematically evaluated and bal-
anced baseline eye diseases. Third, we
used Medicare’s low-income subsidy as a
surrogate marker for socioeconomic risk
factors for DR diagnosis (16). Last, in a
sensitivity analysis, we also restricted the
analysis to patients with an eye exam
after cohort entry,with results consistent
with the primary analysis.
Limitations
Our study has limitations. First, we had
no information on diabetes duration, and
data on measures of glycemic control
were available for only a small propor-
tion of the population. However, we used
surrogate measures of diabetes dura-
tion and glycemic control including age,
diabetes complications, number of hy-
perglycemia diagnoses, and number of
hospitalizations due to diabetes. The
well-balanced covariates and the avail-
able clinical measures suggest our ACNU
design removed unmeasured confound-
ing except for in the GLP1RA versus LAI
comparison. We also performed multiple
imputation for missing clinical data and
conducted several stratified analyses to
minimize the risk that unmeasured con-
founding is responsible for our results.
Second, our algorithm for detection
of the outcome has not been validated
previously. However, we identified our
primary outcome by treatments, which
are specialist procedures that would be
provided only by an ophthalmologist.
Furthermore, for cases identified with
an intravitreal injection procedure code
(67028), we required that it be used
jointly with a HCPCS drug code to min-
imize miscoding of treatments and ex-
cluded patients with specific forms of
AMD that are treated by intravitreal
injections. Therefore, it is unlikely that
patients that met our disease definition
(with diagnosis of diabetes or DR and
received retinopathy treatment) did
not receive treatment for retinopathy.
A highly specific outcome definition
minimizes bias in the HR, even in the
presence of nonperfect sensitivity (40).
Reassuringly, our sensitivity analysis
that modified the outcome definition
to be more specific (with DR diagnosis
and evidence of receiving retinopa-
thy treatments) produced results that
were consistent with those of our pri-
mary analysis.
Last, we only assessed short-term IBT
use, as the real-world adherence is low
(14). The short follow-up in this study
may impair the potential for detecting
differences with long-term use of these
drugs. Long-term specific studies with
systematic grading of DR and consider-
ation of significant clinical variables
such as diabetes duration, HbA1c, and
hypertension are urgently needed.
Summary
Our population-based, ACNU cohort study
of older U.S. adults with diabetes sug-
gests that the real-world use of IBTs over
an average of less than 1 year does not
increase the risk of DR compared with
alternatives.
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Storm P, Groop L, Gustavsson C. Prevalence
and risk factors for diabetic retinopathy at di-
agnosis (DRAD) in patients recently diagnosed
with type 2 diabetes (T2D) or latent autoim-
mune diabetes in the adult (LADA). J Diabetes
Complications 2016;30:1456–1461
17. Sato T, Matsuyama Y. Marginal structural
models as a tool for standardization. Epidemi-
ology 2003;14:680–686
18. Cole SR, Hernán MA. Adjusted survival
curves with inverse probability weights. Comput
Methods Programs Biomed 2004;75:45–49
19. National Committee for Quality Assurance.
The Healthcare Effectiveness Data and Information
Set (HEDIS) measures. Available from http://www
.ncqa.org/hedis-quality-measurement/hedis-
measures. Accessed 10 April 2018
20. Bagley B. Measuring for Medicare: the Phy-
sicianQuality Reporting Initiative. Available from
https://www.aafp.org/fpm/2007/0600/p37.pdf.
Accessed 10 April 2018
21. Rubin DB. Multiple Imputation for Nonre-
sponse in Surveys. Hoboken, NJ, John Wiley &
Sons, 2004
22. Silva PS, Aiello LP. Telemedicine and eye
examinations for diabetic retinopathy: a time to
maximize real-world outcomes. JAMA Ophthal-
mol 2015;133:525–526
23. The Diabetes Control and Complications
Trial Research Group. Early worsening of diabe-
tic retinopathy in the Diabetes Control and
Complications Trial. Arch Ophthalmol 1998;116:
874–886
24. Makri OE, Georgalas I, Georgakopoulos CD.
Drug-induced macular edema. Drugs 2013;73:
789–802
25. Nencini C, Barberi L, Runci FM, Micheli L.
Retinopathy induced by drugs and herbal med-
icines. Eur Rev Med Pharmacol Sci 2008;12:
293–298
26. Stürmer T, Glynn RJ, Rothman KJ, Avorn J,
Schneeweiss S. Adjustments for unmeasured
confounders in pharmacoepidemiologic data-
base studies using external information. Med
Care 2007;45(Suppl. 2):S158–S165
27. Stürmer T,MarquisMA, ZhouH, et al. Cancer
incidence among those initiating insulin therapy
with glargine versus human NPH insulin. Diabe-
tes Care 2013;36:3517–3525
28. Wahl S, Boulesteix AL, Zierer A, Thorand B,
van de Wiel MA. Erratum to: Assessment of
predictive performance in incomplete data by
combining internal validation and multiple im-
putation. BMC Med Res Methodol 2016;16:
170
29. Sterne JA, White IR, Carlin JB, et al. Multiple
imputation for missing data in epidemiological
and clinical research: potential and pitfalls. BMJ
2009;338:b2393
30. U.S. Food and Drug Administration. Drugs@
FDA: FDA approved drug products. Tanzeum
Albiglutide. Available from https://www.accessdata
.fda.gov/scripts/cder/daf/index.cfm?event=overview
.process&ApplNo=125431. Accessed 17 October
2017
31. U.S. Food and Drug Administration. Drugs@
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